Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNB4 | O00305 | 1/20 | 0.43 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.43 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.43 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.43 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.43 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.43 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.43 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.43 |
| ▸ | CACNG1 | Q06432 | 1/20 | 0.43 |
| ▸ | CACNB2 | Q08289 | 1/20 | 0.43 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.43 |
| ▸ | CACNA1E | Q15878 | 1/20 | 0.43 |
| ▸ | CACNA2D4 | Q7Z3S7 | 1/20 | 0.43 |
| ▸ | CACNA2D3 | Q8IZS8 | 1/20 | 0.43 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17687881 | 0.92 | BTK (0.47) | FFAR4USP30BTKGPR119PIK3CD | |
| SCHEMBL17687939 | 0.92 | BTK (0.47) | FFAR4USP30BTKGPR119PIK3CD | |
| SCHEMBL17687877 | 0.92 | BTK (0.47) | FFAR4USP30BTKGPR119PIK3CD | |
| SCHEMBL17687852 | 0.92 | USP30 (0.47) | FFAR4USP30BTKGPR119PIK3CD | |
| SCHEMBL19471534 | 0.89 | USP30 (0.38) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL19471533 | 0.89 | USP30 (0.38) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL19471467 | 0.89 | USP30 (0.37) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL19471469 | 0.89 | USP30 (0.37) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL19471480 | 0.86 | PIK3CD (0.38) | FFAR4USP30GPR119PIK3CD | |
| SCHEMBL17687783 | 0.85 | FFAR4 (0.44) | FFAR4USP30GPR119CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3207042-B1 | ANTIBACTERIAL BASIC BIAROMATIC DERIVATIVES WITH AMINOALKOXY SUBSTITUTION | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-10-03 | — | — | EP | disclosed |
| US-9850256-B2 | Antibacterial basic biaromatic derivatives with aminoalkoxy substitution | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-12-26 | — | — | US | disclosed |
| US-20170305927-A1 | ANTIBACTERIAL BASIC BIAROMATIC DERIVATIVES WITH AMINOALKOXY SUBSTITUTION | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-10-26 | — | — | US | disclosed |
| EP-3207042-A1 | ANTIBACTERIAL BASIC BIAROMATIC DERIVATIVES WITH AMINOALKOXY SUBSTITUTION | Idorsia Pharmaceuticals Ltd (CH) | 2017-08-23 | — | — | EP | disclosed |
| WO-2016059097-A1 | ANTIBACTERIAL BASIC BIAROMATIC DERIVATIVES WITH AMINOALKOXY SUBSTITUTION | ACTELION PHARMACEUTICALS LTD (CH) | 2016-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305927-A1 | ANTIBACTERIAL BASIC BIAROMATIC DERIVATIVES WITH AMINOALKOXY SUBSTITUTION | RPSA, RPL4, RPS4Y1 | CACNB4 1349/4885CACNA1A 627/4885CACNA1G 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.